Omeros Corporation (NASDAQ:OMER – Get Free Report) has been assigned an average rating of “Moderate Buy” from the six analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $38.00.
A number of equities analysts have commented on the stock. Wall Street Zen lowered shares of Omeros from a “buy” rating to a “hold” rating in a report on Sunday, June 7th. D. Boral Capital restated a “buy” rating and set a $36.00 target price on shares of Omeros in a research note on Tuesday, April 21st. Zacks Research lowered Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Weiss Ratings cut Omeros from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, June 2nd. Finally, HC Wainwright reduced their price target on Omeros from $40.00 to $33.00 and set a “buy” rating for the company in a report on Friday, June 26th.
View Our Latest Stock Analysis on Omeros
Insider Transactions at Omeros
Institutional Trading of Omeros
Hedge funds and other institutional investors have recently made changes to their positions in the stock. State of Wyoming acquired a new stake in Omeros in the fourth quarter valued at $25,000. Caitong International Asset Management Co. Ltd acquired a new position in Omeros during the 4th quarter worth $33,000. Assetmark Inc. bought a new stake in shares of Omeros in the 1st quarter worth about $38,000. Arax Advisory Partners increased its position in shares of Omeros by 56.4% in the 4th quarter. Arax Advisory Partners now owns 5,255 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 1,894 shares during the last quarter. Finally, International Assets Investment Management LLC raised its stake in shares of Omeros by 16.0% in the 1st quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 800 shares in the last quarter. Institutional investors own 48.79% of the company’s stock.
Omeros Stock Up 4.5%
OMER opened at $10.28 on Tuesday. The firm’s 50 day moving average is $10.32 and its 200-day moving average is $11.51. Omeros has a 52-week low of $3.43 and a 52-week high of $17.65. The firm has a market capitalization of $744.07 million, a P/E ratio of 14.69 and a beta of 2.55.
Omeros (NASDAQ:OMER – Get Free Report) last announced its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.16. The firm had revenue of $9.89 million during the quarter, compared to analysts’ expectations of $4.19 million. Equities analysts expect that Omeros will post -0.94 earnings per share for the current fiscal year.
Omeros Company Profile
Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.
Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.
Featured Stories
- Five stocks we like better than Omeros
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
